KRW 15050.0
(-4.57%)
Year | Total Assets | Total Assets Growth |
---|---|---|
2023 | 711.72 Billion KRW | -4.03% |
2022 | 741.6 Billion KRW | 48.38% |
2021 | 499.81 Billion KRW | -17.27% |
2020 | 604.16 Billion KRW | 277.37% |
2019 | 160.09 Billion KRW | 55.55% |
2018 | 102.92 Billion KRW | 149.51% |
2017 | 41.24 Billion KRW | 0.0% |
Year | Total Assets | Total Assets Growth |
---|---|---|
2023 Q4 | 711.72 Billion KRW | 0.2% |
2023 Q1 | 739.82 Billion KRW | -0.24% |
2023 Q3 | 710.29 Billion KRW | 1.26% |
2023 Q2 | 701.45 Billion KRW | -5.19% |
2022 Q1 | 769.73 Billion KRW | 54.0% |
2022 Q2 | 697.75 Billion KRW | -9.35% |
2022 FY | 741.6 Billion KRW | 48.38% |
2022 Q4 | 741.6 Billion KRW | -2.54% |
2022 Q3 | 760.89 Billion KRW | 9.05% |
2021 Q1 | 638.94 Billion KRW | 5.76% |
2021 FY | 499.81 Billion KRW | -17.27% |
2021 Q4 | 499.81 Billion KRW | -13.4% |
2021 Q3 | 577.11 Billion KRW | -11.08% |
2021 Q2 | 649.04 Billion KRW | 1.58% |
2020 Q4 | 604.16 Billion KRW | 0.82% |
2020 Q3 | 599.26 Billion KRW | 0.0% |
2020 FY | 604.16 Billion KRW | 277.37% |
2019 FY | 160.09 Billion KRW | 55.55% |
2019 Q4 | 160.09 Billion KRW | 0.0% |
2018 FY | 102.92 Billion KRW | 149.51% |
2017 FY | 41.24 Billion KRW | 0.0% |
Name | Total Assets | Total Assets Difference |
---|---|---|
ORIENT BIO Inc. | 96.98 Billion KRW | -633.825% |
Green Cross Holdings Corporation | 3737.7 Billion KRW | 80.958% |
Green Cross Holdings Corporation | 2643.31 Billion KRW | 73.075% |
Pharmicell Co., Ltd. | 99.19 Billion KRW | -617.523% |
Green Cross Corporation | 2643.31 Billion KRW | 73.075% |
GeneOne Life Science, Inc. | 151 Billion KRW | -371.314% |
Celltrion, Inc. | 19917.53 Billion KRW | 96.427% |
Samsung Biologics Co.,Ltd. | 16046.19 Billion KRW | 95.565% |
SK bioscience Co.,Ltd. | 1852.43 Billion KRW | 61.579% |
SK Biopharmaceuticals Co., Ltd. | 723.17 Billion KRW | 1.583% |